Adverse drug reaction patterns of GLP ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database

Analysis involved 24,725 individuals using liraglutide, 21,454 using semaglutide, and 11,538 using tirzepatide.

• Tirzepatide had fewer reports of adverse drug reactions compared to liraglutide and semaglutide.
• The strength of the pharmacovigilance association for tirzepatide was the lowest among the three medications.
• Semaglutide was significantly associated with unusual adverse events, including suicidal ideation and behavior.
• Other notable adverse events linked to semaglutide included hair loss and vision loss.
• Statistical analysis indicated that the associations between semaglutide and these adverse events were significant.

AI simplified